As a physician (not an oncologist), the GS report confirms what colleagues (who are oncs.) are saying and doing. They were well aware of Ibrut./Imbruv well before it was approved for r/r CLL and Rxing off label. Most impressive besides short term results was low incidence of adverse events/side effects. Lab results confirmed what was being seen during phase III studies and they are still awaiting diagnostic imaging verification. But the most important thing they are seeing is overall patient improvement in terms of increased stamina and overall "feeling much better".
Let the day traders make their few bucks and let the mgt. at PCYC make their big bucks with options. Stick the course....next focus group are the rheumatologists.
Morty, if you're so sure.....short the hell out of PCYC.......some more. See where that gets yuh.
Marky....tell us how you did with PCYC today. Did you get to cover that "POS" at 70 like you predicted a few weeks ago? Guess not! And now you're in the same boat with GALE, trying the same obvious tactics and hopefully the same results.
The article is dated from Jan. 2013 and as noted is old old news. And the implications?? Will all patients and oncologists be required to convert before they can prescribe and use drug? What is the point in bringing this up? Oh yeah, you're also are trying to protect us from making a bad investment. The absurdity of bringing up old news is self evident. Please spare us.
Time will tell Morty....let's see where we are 6 months from now. And please, don't worry about my finances as to when I sell PCYC. I know you're just trying to be "helpful", but where were you when SP at $140....not much gloom and doom then. You pop up when SP down and make it sound like you have a clue as to next move. Your posts are worthless.